Apellis Pharmaceuticals, Inc.APLSNASDAQ
Loading
R&D Expenses Over TimeStable
Percentile Rank58
3Y CAGR-8.6%
5Y CAGR-0.3%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
-8.6%/yr
vs +38.5%/yr prior
5Y CAGR
-0.3%/yr
Recent deceleration
Acceleration
-47.1pp
Decelerating
Percentile
P58
Within normal range
vs 5Y Ago
1x
Modest growth
Streak
4 yr
Consecutive declineStable
PeriodValueYoY Change
TTM$295.85M-9.7%
2024$327.57M-7.6%
2023$354.39M-8.5%
2022$387.24M-8.0%
2021$420.87M+40.3%
2020$299.92M+35.7%
2019$220.97M+109.9%
2018$105.29M+161.2%
2017$40.30M+75.4%
2016$22.98M-